Form 4: Teva Pharmaceutical Industries Exec VP Richard Daniell Reports Share Sales

Executive Vice President of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports the sale of ordinary shares to cover tax obligations and pursuant to a pre-arranged trading plan.

Summary

• Richard Daniell, Executive Vice President of European Commercial at Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the sale of ordinary shares on March 4 and 5, 2025, at weighted average prices of $15.7346 and $15.9132, respectively.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 19, 2024.
• The sales were also to cover tax withholding obligations related to the vesting of restricted share units.
• Daniell also acquired shares through the vesting of restricted share units on March 4, 2025.
• Following these transactions, Daniell directly owns 96,769 ordinary shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reflects routine transactions related to executive compensation and pre-planned sales under a 10b5-1 plan. There's no indication of unusual or concerning activity.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a company executive.
• The impact is likely limited as the sales were conducted under a pre-arranged trading plan and to cover tax obligations.

Key Dates